We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 63.00 | 15,341 | 07:36:40 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:22:52 | O | 7,642 | 61.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 15/4/2024 | 11:06 | ALNC |  NetScientific investee secures funding to develop product range |
| 15/4/2024 | 07:00 | UK RNS | NetScientific PLC ProAxsis secures c.£1.8mn investment |
| 27/3/2024 | 18:47 | ALNC | TRADING UPDATES: Empire Metals targets key milestones in Australia |
| 27/3/2024 | 13:34 | UK RNS | NetScientific PLC PDS Strategy Update and 2023 Financial Results |
| 13/3/2024 | 17:04 | ALNC | NetScientific "significantly" advances strategic goals |
| 13/3/2024 | 07:00 | UK RNS | NetScientific PLC Business Update |
| 05/2/2024 | 07:00 | UK RNS | NetScientific PLC Exercise of Options and Issue of Shares |
| 23/1/2024 | 18:39 | ALNC | TRADING UPDATES: Esken's Southend Airport faces further allegations |
| 23/1/2024 | 07:00 | UKREG | NetScientific PLC Glycotest secures $1 million investment |
| 01/12/2023 | 11:59 | ALNC | IN BRIEF: NetScientific investee DeepTech Recycling bags GBP1 million |
Netscientific (NSCI) Share Charts1 Year Netscientific Chart |
|
1 Month Netscientific Chart |
Intraday Netscientific Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/4/2024 | 12:16 | NetScientific PLC | 5,746 |
| 24/1/2021 | 19:11 | NETSCIENTIFIC | 10 |
| 15/6/2019 | 11:31 | Netscientific | 16 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:22:53 | 61.40 | 7,642 | 4,692.19 | O |
| 11:22:39 | 61.00 | 7,699 | 4,696.39 | O |
| Top Posts |
|---|
Posted at 19/4/2024 09:20 by Netscientific Daily Update Netscientific Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 63p.Netscientific currently has 23,574,303 shares in issue. The market capitalisation of Netscientific is £14,851,811. Netscientific has a price to earnings ratio (PE ratio) of -4.80. This morning NSCI shares opened at 63p |
Posted at 18/4/2024 12:16 by kingston78 There are increments in the value of the company's investments, without or with little further capital outlay, as those investments attract external funding.However, these increases in value are not realised and therefore many investors do not give it credence. Only when some or all of those investments are realised by selling them for cash will more investors recognise the true value of NSCI. Looking at past announcements, I feel that it will not be too far away when a total exit from one or more investments will take place. Watch this space for the share price to shoot up without warning. |
Posted at 16/4/2024 23:20 by loafofbread Still can't quite believe we have only gained 1p on that news.If they are going to sell the lot this summer for £10M in cash? then I hope they put a share buy back into the mix post results. About time they started narrowing the discount of the 60p share price to the £2.00 asset value. |
Posted at 15/4/2024 08:06 by blakieboy7 wtf does the share price not move on this RNS? It spells it out in black and white |
Posted at 19/2/2024 14:53 by btgman I am very relaxed with NSCI it is a matter of when not if. Their underlying assets are multiples of current share price. Very little stock around on this one. I doubt whatever is around is going to last very long.AIMHO GLA BTG |
Posted at 17/11/2023 08:17 by loafofbread Much easier if they just posted a normal spread on NSCI.Another £500K increase in PDSB. NSCI share price is so far behind fair value it's unreal. |
Posted at 28/9/2023 15:30 by sev22 A medtech stock with potential to treble in value.The investment company’s portfolio is worth 151 per cent more than its market cap and there are hidden assets, too. September 28, 2023 By Simon Thompson *First-half pre-tax loss of £1.6mn *Fair valuation of portfolio down from £41.8mn to £35.5mn (151p) *Post-period-end disposals improve cash position Aim-traded investment company Netscientific's (NSCI:60p) headline losses mask an improving trading performance. More than three-quarters of the flat first-half operating loss of £1.6mn was due to the consolidated losses of two subsidiary companies: Glycotest, a Philadelphia-based liver disease diagnostics company that is commercialising new and unique blood tests for life-threatening liver cancers and fibrosis-cirrhosis; and ProAxsis, a commercial medical technology company with a focus on respiratory diagnostics. Importantly, both companies are being funded by third-party sources as they move towards the commercialisation stage and do not require funding from Netscientific. Excluding Glycotest and ProAxsis, the group operating loss more than halved to £0.3mn. Moreover, current borrowings of £1.5mn reflect the debt of the two subsidiaries. At a parent level, Netscientific had net cash of £0.3mn on 26 September 2023 and it holds 1.33mn shares worth £5.5mn (23.5p) in PDS Biotechnology Corporation (US: PDSB – $5.10), a $157mn market capitalisation clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines based on its proprietary Versamune T-cell activating technology platform. The fall in PDS’s share price proved a £9.4mn drag on the portfolio valuation, but this was partly offset by net gains of £3.1mn from three other holdings: Vortex Biotech, Q-Bot and DName-IT. The group’s 25 per cent stake in Vortex Biotech quadrupled in value to £2.8mn after the company raised £3.2mn in an enterprise investment scheme (EIS) investment round in June 2023. It was led by EMV Capital, the group’s corporate finance boutique. Vortex’s core technology allows for the capture and isolation of high-quality circulating tumour cells from blood samples. University of Leuven spin-out DName-IT has developed a platform to avoid sample authentication errors and to correct for sample contamination in genetic sequencing laboratory tests. The company operates at the crossroads of the major, growing markets of liquid biopsy, laboratory services, clinical trials and next-generation sequencing. A recent £0.5mn EIS investment round led by EMV Capital increased the valuation of the group’s 36.9 per cent stake from £0.1mn to £1mn. Netscientifc also booked a £0.3mn gain on its £4.1mn holding in Q-Bot, a London-based robotics and artificial intelligence company that has developed a patented energy-saving robotic system for applying insulation in tight spaces and suspended floors (to reduce heat loss and prevent draughts, damp and mould). Hidden value in EMV Capital’s carried interests. The £35.5mn (151p) fair valuation of the portfolio is not only 151 per cent higher than Netscientific’ EMV’s business model is to syndicate investments between financial and corporate investors, and for its management team to take a strong hands-on role post-investment. Monetisation is through a mixture of corporate finance fees, management and incubation services, and carried interests in the investments it syndicates. True, it is difficult to estimate the current value of these stakes. However, based on an average two times portfolio return on CUA, they could deliver carry returns in excess of £4.5mn (19p) to EMV, or a third of its market capitalisation. When I suggested buying the shares, at 64p, in my 2023 Bargain Share Portfolio, I highlighted the potential to make profitable exits on the portfolio. This is starting to happen as the group has made £0.8mn of partial exits since July 2023, which provides funding and is supportive of the fair valuations of investee companies. With sum-of-the-parts valuations almost three times the current share price, the shares remain a buy. |
Posted at 30/6/2023 10:25 by kingston78 Most of us are losing patience not because of lack of progress by the company but for the stagnation or regression of the share price. There is a big disconnect between the value and increasing accretion of value and the share price.The beauty of the company's corporate plan is to get external funding for its portfolio companies and to enhance their value at a higher subscription price. There will be crystallisation of gains in cash terms one of these days. The share price will explode once this happens. |
Posted at 31/5/2023 16:57 by blakieboy7 PDSB now up over 9 dollars, not that it's making FA difference to NSCI share price!! That's over 5.5% up so far |
Posted at 09/5/2023 11:41 by kingston78 Rainbow Rare Earth has raised £7.2 million by private placement at a PREMIUM of 28% to its share price.If there is strong support for a good investment case some investors are happy to pay at a premium. Put it another way, if those investors want to buy a large amount of shares in the open market they will push up the share price anyway. I am waiting for the day when NSCI announces a significant gain by floating or disposing of one or more of its investments, the sums of which will be more than the entire capitalisation at its current share price. There will be a quantum leap that its share price will double or triple instantly. |
Posted at 21/12/2022 11:52 by kingston78 I didn't have trading facility to buy American shares otherwise I would have invested in PDSB when its share price fell below US$4 several months ago. At that time, NSCI was at about the same price as now, and yet PDSB has since propelled from under US4 to about US$ 10. NSCI has hardly increased in value, so this does not make sense. Moreover, consensus of one year target price for PDSB has been trimmed from US$20 to US$17, with strong buy amongst American brokers.In any case, I am absolutely convinced that the low share price is due to lack of promotion by the company officers and brokers rather than by market makers. Market makers buy and sell and they don't care whether the price is high or low. They make a turn at every trade. If investor demand is high the share price will go up and vice versa. I am familiar with the corporate world. I believe that any one of its portfolio companies could be worth more as a standalone company than the current entire group of NSCI. NSCI ridiculously cheap at its current price. There were times when brokers talked of 200 p each. Even their conservative estimates now say that it is worth at least 120 p. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
